unaudited financial results for q and year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sandu Pharmaceuticals reported its unaudited standalone results for Q2 FY26 and H1 FY26. Q2 revenue from operations rose about 6% YoY to Rs 1,762.11 lakhs (from Rs 1,663.01 lakhs). Net profit for the quarter jumped roughly 136% YoY to Rs 52.43 lakhs (from Rs 22.23 lakhs), with EPS at Rs 0.54 vs Rs 0.23. For the half year, revenue was Rs 3,432.01 lakhs, marginally lower than Rs 3,475.93 lakhs in H1 FY25, while H1 PAT grew about 12% to Rs 74.78 lakhs and EPS rose to Rs 0.77. The company operates in a single segment, Ayurvedic Proprietary Medicines. Operating cash flow for the half year was strong at Rs 241.84 lakhs. Statutory auditor M/s. Dileep & Prithvi issued an unqualified limited review report.
Sharp Q2 profit growth and improved operating margin are positive signals for shareholders, but the H1 revenue dipped slightly and overall half-year PAT growth was modest, suggesting the Q2 surge is what drove the improvement. The clean auditor report and healthy cash flow are reassuring; investors should track whether the margin gains hold in coming quarters.